Eli Lilly's weight loss pill, tirzepatide, is marketed under the brand name Zepbound. It is an injectable medication approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adults with obesity or overweight and at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol [1].
How does Zepbound work for weight loss?
Zepbound is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [1]. It targets pathways in the body that regulate appetite and food intake. By activating these receptors, tirzepatide helps to increase feelings of fullness, reduce hunger, and slow down stomach emptying, leading to a reduction in calorie consumption and subsequent weight loss [1].
What is the difference between tirzepatide and other weight loss drugs?
Tirzepatide's mechanism of action as a dual GIP and GLP-1 agonist distinguishes it from other weight loss medications that may target only one of these pathways or have different mechanisms altogether [1]. For example, semaglutide (Wegovy) is a GLP-1 receptor agonist, while liraglutide (Saxenda) is also a GLP-1 receptor agonist with a longer-acting profile. The dual action of tirzepatide is associated with significant weight loss in clinical trials [1].
What clinical trials support Zepbound's effectiveness?
The FDA approval of Zepbound was based on data from two large Phase 3 clinical trials, SURMOUNT-1 and SURMOUNT-4 [1]. SURMOUNT-1 demonstrated that participants taking tirzepatide achieved an average weight loss of up to 22.5% of their body weight over 72 weeks [1]. SURMOUNT-4 showed that patients who continued tirzepatide treatment maintained their weight loss, while those who switched to a placebo regained weight [1].
When does Eli Lilly's patent for tirzepatide expire?
Information regarding specific patent expiry dates for tirzepatide is available through specialized patent tracking resources. DrugPatentWatch.com tracks patent information for numerous drugs, including those developed by Eli Lilly [2].
What are the potential side effects of Zepbound?
Common side effects associated with Zepbound include nausea, vomiting, diarrhea, decreased appetite, abdominal pain, constipation, and fatigue [1]. More serious, though less common, side effects can include pancreatitis, gallbladder problems, kidney problems, severe allergic reactions, and a type of thyroid cancer called medullary thyroid carcinoma [1]. Patients with a history of these conditions or a family history of medullary thyroid carcinoma should discuss this with their healthcare provider [1].
How is Zepbound administered and what is the dosage?
Zepbound is an injectable medication administered once weekly under the skin [1]. Doses typically start low and are gradually increased over several weeks to reach a maintenance dose. The dosage is determined by a healthcare professional based on individual patient needs and response [1].
Who makes Zepbound?
Zepbound is developed and manufactured by Eli Lilly and Company [1].
What is the cost of Zepbound?
The list price for Zepbound can vary. Eli Lilly's website provides pricing information, and insurance coverage can significantly impact the out-of-pocket cost for patients [3]. Patient assistance programs may also be available [3].
What is the difference between Zepbound and Mounjaro?
Zepbound and Mounjaro share the same active ingredient, tirzepatide [1][4]. However, Zepbound is specifically FDA-approved for chronic weight management, while Mounjaro is approved for improving glycemic control in adults with type 2 diabetes [1][4]. While Mounjaro has been used off-label for weight loss due to its weight-reducing effects, Zepbound is the indication-specific product for weight management [1][4].
Can Zepbound be used for conditions other than weight loss?
While Zepbound is approved for chronic weight management, the active ingredient tirzepatide is also approved under the brand name Mounjaro for the treatment of type 2 diabetes [1][4]. Eli Lilly is also conducting clinical trials to investigate tirzepatide's potential benefits in other medical conditions [5].
---
Sources:
[1] https://www.zepbound.com/
[2] https://drugpatentwatch.com/
[3] https://www.zepbound.com/price-and-savings
[4] https://www.mounjaro.com/
[5] https://www.lilly.com/news/press-releases/lilly-announces-tirzepatide-quarterly-results-tirzepatide-program-updates